Early detection of cardiac dysfunction in childhood cancer survivors; a DCOG LATER study
- Conditions
- Cardiotoxicity in childhood cancer survivorsCancer treatment related cardiac dysfunction and heart failure
- Registration Number
- NL-OMON23641
- Lead Sponsor
- Princess Maxima Center for pediatric oncology, Amsterdam UMC (AMC), Radboudumc, SKIO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 2200
Eligible survivors are 5-year childhood cancer survivors (CCS) diagnosed before the age of 18 years, between 1/1/1963 and 12/31/2001 with a malignancy according to the third edition of the International Classification of Childhood Cancer. We only included CCS who were living in the Netherlands at the time of childhood cancer diagnosis and who were treated in one of the Dutch pediatric oncology/hematology centers (Academic Medical Center Amsterdam, VU University Medical Center, Leiden University Medical Center, Erasmus Medical Center, University Medical Center Groningen, Radboudumc, and University Medical Center Utrecht). This study will include 4 risk groups; risk group 1: CCS who have received anthracyclines, mitoxantrone, or irradiation to the heart region; risk group 2 (max n=100): cyclophosphamide only (no anthracyclines, mitoxantrone, or irradiation to the heart region, ifosfamide or vincristine); risk group 3 (max n=100): ifosfamide only (no anthracyclines, mitoxantrone, or irradiation to the heart region, cyclophosphamide or vincristine); risk group 4 (max n=100): vincristine only (no anthracyclines, mitoxantrone, or irradiation to the heart region, ifosfamide or cyclophosphamide), irrespective current age. For the comparison group 500 healthy siblings will be included.
N/A
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method